...NYSE:JNJ) gained through its 2017 acquisition of Actelion Ltd.: Opsumit macitentan, Uptravi selexipag and Tracleer bosentan. Stephen...

...Janssen Pharmaceutical Research and Development on the study, which evaluated eight products including approved drugs bosentan...
...chip platform to enable better decision making in drug discovery and development." Geraldine Hamilton, Emulate Bosentan...

...metabolic disorders such as phenylketonuria, Pompe disease and Gaucher disease. Drugs for PAH include Tracleer bosentan...
...and Ofev/Vargatef nintedanib from Boehringer Ingelheim GmbH (Ingelheim, Germany). Also included are the APIs for bosentan...

...in place: the Actelion Pharmaceuticals Ltd. unit of Johnson & Johnson (NYSE:JNJ), which markets Tracleer bosentan...

...with myelodysplasia-related changes Johnson & Johnson (NYSE:JNJ) FDA approves a 32 mg tablet of Tracleer bosentan...

...FDA approved a 32 mg tablet of Tracleer bosentan to treat pulmonary arterial hypertension in children...
...Johnson & Johnson (NYSE:JNJ) gained Tracleer in its June acquisition of Actelion Ltd. Actelion said Tracleer...
...Jan. 27 ). Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Tracleer bosentan Business: Cardiovascular Mary Romeo Tracleer Idorsia...

...FDA approved a 32 mg tablet of Tracleer bosentan to treat pulmonary arterial hypertension in children...
...Johnson & Johnson (NYSE:JNJ) gained Tracleer in its June acquisition of Actelion Ltd. Actelion said Tracleer...
...discovery operations and early stage assets (see BioCentury Extra, Jan. 26 and June 16) . Mary Romeo Tracleer Idorsia...

...pointed to the spheroids’ ability to pick out cytotoxicity of the endothelin receptor antagonists Tracleer bosentan...
...prolonged expression of BSEPs is a potential advantage of the system. Johnson & Johnson obtained Tracleer...

...drug Zytiga abiraterone and multiple myeloma therapy Velcade bortezomib, but withdrew Remicade infliximab and Tracleer bosentan...

...bosentan for congestive heart failure (CHF). Roche had discontinued a Phase III trial of bosentan...
...known Orphan indication, pulmonary arterial hypertension (PAH), in parallel with heart failure. FDA approved Tracleer bosentan...
...tied to Tracleer. Despite trials in numerous other indications, the biotech never succeeded in expanding Tracleer’s...